

95-0311

The invention relates to the medicine. The summary of the invention consists in the fact that for the treatment of B cell disorders, and in particular, B cell lymphomas, an effective amount of immunologically active chimeric anti-CD20 antibodies or radiolabeled anti-CD20 antibodies is administered or it is combined the administration thereof.